MARKET

CADL

CADL

Candel Therapeutics, Inc.
NASDAQ
5.65
-0.06
-1.05%
After Hours: 5.65 0 0.00% 19:24 12/31 EST
OPEN
5.71
PREV CLOSE
5.71
HIGH
5.75
LOW
5.52
VOLUME
688.99K
TURNOVER
--
52 WEEK HIGH
13.68
52 WEEK LOW
4.250
MARKET CAP
310.18M
P/E (TTM)
-10.1055
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CADL last week (1222-1226)?
Weekly Report · 12/29/2025 09:39
Weekly Report: what happened at CADL last week (1215-1219)?
Weekly Report · 12/22/2025 09:39
Weekly Report: what happened at CADL last week (1208-1212)?
Weekly Report · 12/15/2025 09:42
Canaccord Genuity Sticks to Their Buy Rating for Candel Therapeutics (CADL)
TipRanks · 12/12/2025 12:18
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday
Benzinga · 12/11/2025 17:18
Candel Therapeutics Showcases Advances in Immune-Based Cancer Therapies in New Corporate Presentation
Reuters · 12/10/2025 20:29
Candel Therapeutics’ Promising CAN-2409 Program Drives Buy Rating Amid Positive Phase 3 Results and Expert Endorsements
TipRanks · 12/08/2025 20:45
Candel Therapeutics Price Target Maintained With a $15.00/Share by Stephens & Co.
Dow Jones · 12/08/2025 14:09
More
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Webull offers Candel Therapeutics Inc stock information, including NASDAQ: CADL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CADL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CADL stock methods without spending real money on the virtual paper trading platform.